Introduction {#S1}
============

Glycosylation is a common posttranslational modification of proteins. Glycans are implicated in a wide range of biological events such as cell--cell interactions and recognition, inflammation, and autoimmune diseases ([@C22]; [@C18]). Detailed knowledge of the glycan structure helps to correlate them to their respective function. To do so, tools are required for highly sensitive analysis of glycan chains. For structural analysis of asparagine-linked carbohydrates (*N*-linked glycans), sugars are released from the protein backbone by enzymes such as PNGase F ([@C20]). The *O*-linked glycans are most commonly attached to serine or threonine residues through the GalNAc residue at the reducing end. Presently, there is no enzymatic way of releasing of *O*-glycans intact. This is achieved by chemical methods, typically by β-elimination with mild alkali ([@C16]) or mild hydrazinolysis ([@C19]). These chemical methods are limited because after this treatment the protein is no longer functional.

Endo-α-*N*-acetylgalactosaminidase (endo-α-GalNAcase, EC 3.2.1.97) catalyzes the hydrolysis of an *O*-glycosidic α-linkage between galactosyl β1,3 *N*-acetyl-D-galactosamine (Galβ1,3GalNAc) and the serine or threonine residue in mucins and mucin-type glycoproteins from various animal sources. This *O*-linked disaccharide (Core 1 type *O*-glycan) is one of the most abundant core structures found in mucin glycoproteins. It is known as the Thomsen-- Friedenreich antigen (T antigen) immunodeterminant group and is used as a specific marker of carcinoma ([@C22]; [@C18]).

Endo-*α*-GalNAcases have been purified from *Clostridium perfringens* ([@C13]), *Streptococcus pneumoniae* ([@C11]; [@C21]; [@C7]), *Alcaligenes* sp. ([@C8]), *Bacillus* sp. ([@C3]), and *Bifidobacterium longum* ([@C10]). All of these enzymes have a strict substrate specificity, acting only on the α-linked disaccharide, Galβ1,3GalNAc. An enzyme isolated from *Streptomyces* sp., has been reported to release longer sugar chains than the disaccharide from porcine mucin ([@C14], [@C15]) although further studies are needed to confirm this activity. These endo-*α*-GalNAcases liberate *O*-linked oligosaccharides from glycoproteins without damaging the protein backbone. This makes these enzymes powerful tools for the investigation of the structure and function of *O*-glycans.

The first gene encoding endo-*α*-GalNAcase was isolated from *B. longum* JCM1217 (*engBF*) ([@C10]). In an effort to identify endo-α-GalNAcases with broader substrate specificity a BLAST search was done ([@C1]) using the EngBF protein sequence as a template. Four potential endo-α-GalNAcases were selected from the BLAST results and their genes were cloned; the expressed proteins were purified and characterized. Two of these enzymes can release Core 1 and Core 3 type *O*-glycans. This is the first report of these enzymes exhibiting this broader substrate specificity.

Results {#S2}
=======

Identification and selection of the putative endo-α-N-acetylgalactosaminidases {#S2-1}
------------------------------------------------------------------------------

In order to identify putative endo-α-GalNAcases, a BLAST ([@C1]) search was run using the endo-α-GalNAcase protein sequence EngBF from *B. longum* JCM1217. The top nine hits were from bacteria and had 28% and higher overall sequence identity with EngBF (Figure [1](#F1){ref-type="fig"}). The predicted molecular mass of EngSP corresponds to that previously characterized from *S. pneumoniae* ([@C7]; [@C11]; [@C21]). All of the putative endo-α-GalNAcases had a centrally located conserved region of 700--800 amino acid residues (Figure [1](#F1){ref-type="fig"}). Using the Pfam database ([@C9]) to analyze the protein sequences, all sequences with the exception of EngEF from *Enterococcus faecalis* contained predicted domains that are presumably involved with the identification or binding of sugars (sugar binding domain (SBD)). To determine if the existence or the positioning of the SBDs could play a role on the substrate specificity of this family of enzymes, it was decided to clone and characterize four of these proteins each with a different organization. EngEF has no predicted SBD. EngPA from *Propionibacterium acnes* has an F5_F8 type C domain (a member of the galactose-binding domain-like superfamily) close to the N-terminus. EngAA from *Arthrobacter aurescens* has two novel putative carbohydrate binding module (NPCBM) domains at the C-terminus. EngCP from *C. perfringens* has a CBM 4_9 domain (carbohydrate binding module) inside the conserved region. All of the other potential endo-α-GalNacases as well as the already characterized enzymes EngBF and EngSP have SBDs at the C-terminus or inside the conserved region (Figure [1](#F1){ref-type="fig"}).

![Schematic representation of the putative endo-α-GalNAcases. Alignment of the putative endo-α-GalNAcases that were revealed by BLAST search against the protein sequence of EngBF and the identity results are shown. The gray shaded boxes correspond to the centrally located conserved region, while the black and patterned boxes indicate different types of SBDs. CBM_4\_9, carbohydrate binding module (Pfam 02018); NPCBM, novel putative carbohydrate binding module (Pfam 08305); FIVAR, uncharacterized sugar-binding domain (Pfam 07554); F5-F8 type C, member of the galactose-binding domain-like superfamily (Pfam 00754). The protein accession numbers are *B. longum* (ABY836679), *R. torques* (ZP_01966813), *B. capillosus* (ZP_02035456), *S. pneumoniae* (YP_873926.1), *E. faecalis* (NP_815498.1), *Janibacter* sp. (ZP_00993766.1), *A. aurescens* (YP_947239.1), *S. coelicolor* (NP_630440.1), *P. acnes* (YP_056270.1), and *C. perfrigens* (YP_695137.1).](cwn069fig1){#F1}

Cloning end expression of the target endo-α-GalNAcase genes {#S2-2}
-----------------------------------------------------------

Oligonucliotide primers (Table [I](#T1){ref-type="table"}) were designed to amplify the genes *eng*EF, *eng*CP, and *eng*AA from the genomic DNA of *E. faecalis* ATCC 700802, *C. perfringens* ATCC 13124, and *A. aurescens TCI*. Following polymerase chain reaction (PCR), the amplified genes were cloned in frame into the pET21a expression vector. Unlike *eng*EF and *eng*CP, expression of *eng*AA was very low. The very weak endo-α-GalNAcase activity of EngAA could be detected using Galβ1,3GalNAcα1*p*NP as a substrate but only after an extended incubation. For this reason, EngAA was dropped from this study. The gene coding the putative endo-α-GalNAcase protein *eng*PA from *P. acnes* could not be amplified by PCR from the genomic DNA of *P. acnes* ATCC25746. To clone the ORF coding for protein EngPA, it was necessary to chemically synthesize the gene using codons optimized for gene expression in *E*scherichia *coli.* Once synthesized the gene was cloned into the expression vector pNEB206A. All three recombinant proteins were purified to apparent homogeneity by the chromatographic steps described in the experimental procedures section. The purified proteins migrated as single bands and the apparent molecular weights were in agreement with the predicted molecular masses (188,000 Da for EngCP, 147,000 Da for EngEF, 142,000 Da for EngPA) (Figure [2](#F2){ref-type="fig"}). Fig. 2Purified endo-α-GalNAcases. SDS--PAGE analysis using 10--20% polyacrylamide gel and stained by Coomassie Brilliant Blue R-250. Lane M, molecular mass standards; lane 1, EngCP; lane 2, EngEF; and lane 3, EngPA.

Substrate specificity {#S2-3}
---------------------

The substrate specificities of the purified enzymes EngCP, EngEF, and EngPA and the commercially available EngSP and EngAL were determined. Each enzyme was incubated with various synthetic substrates. The released sugars were detected by colorimetric assay and thin layer chromatography (TLC) analysis (Table [II](#T2){ref-type="table"}, Figure [3](#F3){ref-type="fig"}). Galβ1,3GalNAcα1*p*NP was the most rapidly hydrolyzed substrate by all the enzymes tested. After 16 h of incubation, only EngEF and EngPA were capable of fully hydrolyzing the Core 3 disaccharide (GlcNAcβ1, 3GalNAcα1*p*NP). EngAL could only partially hydrolyze the Core 3 disaccharide (27%) after 16 h of incubation (Table [II](#T2){ref-type="table"}). EngAL could also partially release GalNAc while the rest of the enzymes released only traces of the monosaccharide (Table [II](#T2){ref-type="table"}). None of the enzymes could act on Galβ1,3GlcNAcα1*p*NP and low or no activity was detected when Core 2 trisaccharide (Galβ1,3(GlcNAcβ1,6)GalNAcα1*p*NP) was used as a substrate (Table [II](#T2){ref-type="table"}).

![TLC analysis of the reaction products using *p*NP substrates and natural glycoproteins. Reaction mixtures were incubated with (lane +) and without (lane −) EngEF at 25°C for 16 h. Lane 1, Core 2 trisaccharide Galβ1,3(GlcNAcβ1,6)GalNAcα1*p*NP; lane 2, Core 3 disaccharide GlcNAcβ1,3GalNAcα1*p*NP; lane 3; Galβ1,3GlcNAcα1*p*NP disaccharide; lane 4, GalNAcα1*p*NP monosaccharide; lane 5, Core 1 disaccharide Galβ1,3GalNAcα1*p*NP; lane 6, Fetuin; lane 7, Fetuin + Neuraminidase; lane 8, Asialofetuin; lane 9, κ-casein glycopeptides; lane 10, κ-casein glycopeptides + Neuraminidase; lane 11, Glycophorin A; lane 12, Glycophorin A + Neuraminidase; lane 13, Mucin glycopeptides; and lane 14, Mucin glycopeptides + Neuraminidase.](cwn069fig3){#F3}

###### 

Primers used for the cloning of the endo-α- *N*-acetylgalactosaminidase genes

  Primer            Sequence
  ----------------- -------------------------------------------
  AAfor-*Nde*I      5′-CC[CATATG]{.ul}CCCCGCTTGTCATCCC-3′
  AArev-*Hind*III   5′-CC[AAGCTT]{.ul}TGCGCAGCTGAACTTCGCG-3′
  EFfor-*Nde*I      5′-CC[CATATG]{.ul}AAACATGGAAAAATAAAACG-
                     ATTTAGTAC-3′
  EFrev-*Xho*I      5′-CC[CTCGAG]{.ul}TTTTTTTGATTCCCCACTGTG-
                     ACCGTAAAG-3′
  CPfor-*Nde*I      5′-CC[CATATG]{.ul}GGTAGAAAATGCATGAATAA-
                     GAAGATTG-3′
  CPrev-*Xho*I      5′-CC[CTCGAG]{.ul}TCTAGCAGTTCTAACAGTTATT-
                     GATTCCTTAG-3′
  PAfor             5′-GGAGACA**U**CCATATGAGTCGCACCC-3′
  PArev             5′- GGGAAAG**U**TTAACGACCTTGACGTGAAAC-3′

Underlined are the restriction sites, while in bold are the uracil residues that are excised from the amplified DNA product by using the USER^TM^ Friendly Cloning Kit ([@C5]).

###### 

Substrate specificity using *p*NP substrates

                                              EngCP   EngEF   EngPA   EngSP   EngAL
  ------------------------------------------- ------- ------- ------- ------- -------
  Galβ1,3GalNAcα1*p*NP (Core 1)               100     100     100     100     100
  Galβ1,3(GlcNAcβ1,6)GalNAcα1*p*NP (Core 2)   2.5     2       0       0.6     0
  GlcNAcβ1,3GalNAcα1*p*NP (Core 3)            6       100     100     3       27
  Galβ1,3GlcNAcα1*p*NP                        0       0       0       0       0
  GalNAcα1*p*NP                               4.4     2.2     1.8     1.2     30

Reaction mixtures were incubated with different endo-α-GalNAcases at 25°C for 16 h. Product release was measured at 405 nm.

The enzymes were also tested for their ability to release sugars from natural glycoproteins. Calf κ-casein, human glycophorin A, porcine mucin, calf fetuin, and calf asialofetuin were incubated with different endo-α-GalNAcases. Based on the TLC analysis, sugars were only released when asialofetuin and mucin where used as substrates (Figure [3](#F3){ref-type="fig"}). Coincubating the substrates with neuraminidase enabled the enzymes to release the core sugars. The released sugars migrated at the same Rf on the TLC plate as the Core 1 and 3 disaccharides (Figure [3](#F3){ref-type="fig"}). As expected from the *p*NP data, when EngAL was incubated with mucin an extra spot at the same Rf as GalNAc was observed (data not shown).

The *k*~cat~ of all enzymes was determined on Gal β1,3GalNAc- α1*p*NP and GlcNAcβ1,3GalNAcα1*p*NP (Table [III](#T3){ref-type="table"}). When Galβ1,3GalNAcα1*p*NP was used as a substrate EngEF exhibited the highest *k*~cat~. EngPA had the lowest activity on that substrate with a *k*~cat~ about 25 times lower than EngEF. In the case of GlcNAcβ1,3GalNAcα1*p*NP the kinetic parameters were determined only for EngPA and EngEF. Interestingly, EngPA had a 3-fold higher *k*~cat~ than EngEF.

###### 

Kinetic parameters of endo-α-GalNAcases using Galβ1,3GalNAcα1*p*NP (Core 1) and GlcNAcβ1,3GalNAcα1*p*NP (Core 3) as substrates

              *k*~cat~ (1/s)   *K*~m~ (μM)
  ----------- ---------------- -------------
  Core 1                       
   EngCP      19.9             70.93
   EngEF      51.17            47.85
   EngPA      2.009            3.781
   EngSP      10.51            40.37
   EngAL      25.89            33.87
   EngBF^a^   17.8             21.8
  Core 3                       
   EngEF      9.434            20.03
   EngPA      28.9             11.15

^a^Data from [@C10].

Transglycosylation activity {#S2-4}
---------------------------

Several endoglycosidases have transglycosylation activity in addition to hydrolysis activity. To test for this activity, Galβ1,3GalNAcα1*p*NP was incubated with various 1-alkanols in the presence of EngCP, EngEF, EngPA, EngSP, and EngAL. Reaction products were analyzed on TLC plates (Figure [4](#F4){ref-type="fig"}). All of the enzymes tested exhibited similar transglycosylation activity. The longest 1-alkanol successfully incorporated in these transglycosylation reactions was 1-pentanol though the level of product was very low (Figure [4](#F4){ref-type="fig"}A and B). EngEF, EngPA, and EngSP were also tested for transglycosylation activity using the disaccharide GlcNAcβ1,3GalNAcα1*p*NP as the donor and 1-alkanols again as the acceptors. Since only EngEF and EngPA were capable of fully hydrolyzing GlcNAcβ1,3GalNAcα1*p*NP compared to the rest of the endo-α-GalNAcases which had very low activity on this substrate (Table [II](#T2){ref-type="table"}), it was surprising to find no significant difference in the amount of transglycosylation products produced by all three enzymes when observed on a TLC (Figure [4](#F4){ref-type="fig"}C).

![TLC analysis of the transglycosylation reactions. Transglycosylation of disaccharide Galβ1,3GalNAcα1*p*NP (**A**, **B**) or GlcNAcβ1,3GalNAcα1*p*NP (**C**) to various 1-alkanols by endo-α-GalNAcases. Lane 1, methanol; lane 2, ethanol; lane 3, 1-propanol; lane 4, 1-butanol; lane 5, 1-pentanol; lane 6, 1-hexanol; lane 7, 1-heptanol; lane 8, 1-octanol; lane 9, 1-nonalol; and lane S, Galβ1,3GalNAcα1*p*NP.](cwn069fig4){#F4}

Discussion {#S3}
==========

This is the first report presenting data about the substrate specificity of all available endo-α-GalNAcases. Three novel endo-α-GalNAcases: EngEF from *E. faecalis*, EngPA from *P. acnes*, and EngCP from *C. perfringens* have been cloned, purified, and characterized. The commercially available endo-α-GalNAcases from *S. pneumoniae* (EngSP) and *Alcaligenes* sp. (EngAL) have also been tested. Data from a previous report on EngBF from *B. longum* ([@C10]) have also been included. All six of these enzymes were able to completely hydrolyze Core 1 disaccharide Galβ1,3GalNAcα1*p*NP. None of them could act on Galβ1,3GlcNAcα1*p*NP showing that there is a strict preference for GalNAc as the sugar participating in the *O*-glycosidic linkage. EngEF exhibited the highest *k*~cat~ on Galβ1,3GalNAcα1*p*NP while EngPA had the lowest.

EngEF and EngPA were the only enzymes in this study able to fully hydrolyze the Core 3 disaccharide (GlcNAcβ1,3GalNAcα1*p*NP). EngAL could partially hydrolyze it (Table [II](#T2){ref-type="table"}) while EngCP, EngSP, and EngBL had even lower activity on this substrate (less than 6%). Interestingly, EngPA was more active on the Core 3 substrate than EngEF contrary to the results on the Core 1 disaccharide (Table [III](#T3){ref-type="table"}). A detailed mutagenesis study will help in identifying the functional residues responsible for the ability of EngEF and EngPA to act on Core 3 disaccharides.

Unfortunately, none of the enzymes could act on natural glycoproteins prior to treatment with neuraminidase. A major challenge would be to design an endo-α-GalNAcase that could act on sialyated *O*-glycans.

All the enzymes were tested for their transglycosylation activity. When the enzymes were incubated in the presence of Galβ1,3GalNAcα1*p*NP and several 1-alkanols, we observed no major differences in the amount of transglycosylation products produced (Figure [4](#F4){ref-type="fig"}A and B). EngEF, EngPA, and EngSP were also tested for transglycosylation activity using GlcNAcβ1,3GalNAcα1*p*NP as a donor. Interestingly, the same transglycosylation activity profile for these three enzymes was observed with this donor (Figure [4](#F4){ref-type="fig"}C) even though only EngEF and EngPA are capable of fully hydrolyzing GlcNAcβ1,3GalNAcα1*p*NP in contrast to EngSP which is significantly less active on this substrate.

After submission of this manuscript, a characterization of EngBF from *B. longum* and EngCP from *C. perfringens* was published ([@C2]). Their results for the substrate specificity of EngCP agreed closely with the substrate specificity we had observed for EngCP.

In this study, three endo-α-GalNAcases were cloned, purified, and characterized. This is the first report of these endo-α-GalNAcases EngEF and EngPA acting on Core 3 in addition to Core 1 *O*-glycans. This property could make these enzymes a powerful tool for the release of *O*-glycan sugars from glycoproteins. They can also be used as templates in future protein engineering experiments toward the creation of endo-α-GalNAcases capable of acting on *O*-linked glycans regardless of their sugar composition.

Materials and methods {#S4}
=====================

Cloning and expression of the endo-α-GalNAcase genes {#S4-1}
----------------------------------------------------

Based on the DNA sequence of AAO81568 from *E. faecalis*, YP_695137.1 from *C. perfringens*, and YP_947239.1 from *A. aurescens*, oligonucleotide primer pairs EFfor-*Nde*I/EFrev-*Xho*I, CPfor-*Nde*I/CPrev-*Xho*I, and AAfor-*Nde*I/AArev-*Hind*III were designed (Table [I](#T1){ref-type="table"}). The putative endo-α-GalNAcase genes were amplified by PCR using these primer pairs from the genomic DNA of *E. faecalis* ATCC 700802, *C. perfringens* ATCC 13124, and *A. aurescens TC1*, respectively. The amplified genes (*engEF*, *engCP*, and *engAA*) were digested with the appropriate restriction enzymes (New England Biolabs, Inc., Ipswich, MA) and inserted into the corresponding sites of pET-21a (Novagen, Madison, WI). The resulting plasmids (pET21a-*engEF*, pET21a-*engCP*, and pET21a-*engAA*) were transformed into *E. coli* T7 Express *lysY* (New England Biolabs, Inc., Ipswich, MA). The transformed cells were grown overnight at 30°C in a 20 mL LB medium containing 100 μg/mL ampicillin. These transformations were used to inoculate 1000 mL of fresh medium and antibiotics and grown at 25°C. After these cultures reached an *A*~600~ of 0.6--0.7, 0.3 mM isopropyl thio-β-D-galactopyranoside was added and the cultures were shifted to 20°C. Incubation was continued for 12--14 h. The cells were harvested by centrifugation. The cell pellet was suspended in a final volume of 15 mL of 20 mM Tris--HCl, pH 7.6, 200 mM NaCl, 1 mM dithiothreitol. The resuspended cells were sonicated for eight 20-s bursts at 50% duty cycle using a Sonicator Ultrasonic processor model-375 (Misonix, Farmingdale, NY). Samples were subsequently centrifuged and the supernatant was collected for further purification. All purification steps were carried out at 4°C. All columns used for protein purification were purchased from GE Healthcare (Piscataway, NJ).

Based on the DNA sequence of YP_056270.1 from *P. acnes*, the putative endo-α-GalNAcase gene was chemically synthesized. The codons were optimized for gene expression in *E. coli* using DNAWorks software ([@C12]). The optimized sequence was divided into six building blocks and synthesized ([@C12]). After the sequence of each block was verified, the full sized gene was assembled using the USER method ([@C5]). Once assembled the synthesized *engPA* gene was amplified by PCR using the primer pair PAfor/PArev (Table [I](#T1){ref-type="table"}) and inserted into the corresponding sites of pNEB206A using the USER^TM^ Friendly Cloning Kit (New England Biolabs, Inc., Ipswich, MA) ([@C5]). The resulting plasmid pNEB206A-*engPA* was transformed, expressed, and lysed as previously described for other endo-α-GalNAcase genes.

EngEF purification {#S4-2}
------------------

The cell extract was diluted 3-fold with a buffer containing 20 mM Tris--HCl, pH 7.6 (buffer A) and loaded onto a HiTrap Q HP column that had been previously equilibrated in buffer A. After the column was washed with five column volumes of buffer A, the enzyme was eluted with a linear gradient of 0--1 M NaCl in buffer A. Fractions with the enzyme eluted from 0.2 to 0.75 M NaCl. This was pooled and loaded onto a HisTrap HP column previously equilibrated with buffer B (20 mM Tris--HCl, pH 7.6, 500 mM NaCl). After the column was washed with five column volumes of buffer B, the enzyme was eluted with a linear gradient of 0--0.5 M imidazole in buffer B. The peak of enzyme activity eluted at an imidazole concentration range of 0.06--0.27 M. These fractions were combined, dialyzed overnight against buffer A, and loaded onto a Source 15Q column equilibrated in buffer A. After the column was washed with five column volumes of buffer A, the proteins were eluted with a linear gradient of 0.1--0.23 M NaCl in buffer A. Active EngEF eluted from 0.14 to 0.18 M NaCl. These fractions were combined and concentrated with a Centricon Concentrator 10 (Millipore, Billerica, MA) to about 5 mL. Concentrated samples were loaded onto a Superdex 75 column previously equilibrated with buffer C (20 mM Tris--HCl, pH 7.6, 200 mM NaCl) and washed with buffer C. Fractions with EngEF activity were pooled and concentrated. After the addition of glycerol at 50%, the purified enzyme preparation was stored at −20°C. Enzyme purity was judged by gradient polyacrylamide gel electrophoresis under denaturing conditions ([@C17]). Protein concentration was determined using Bradford\'s dye binding assay (Bio-Rad, Hercules, CA) ([@C6]). Highly purified bovine serum albumin (Thermo Fisher Scientific Inc., Pittsburgh, PA) was used as the protein standard.

EngCP purification {#S4-3}
------------------

The cell extract was diluted 3-fold with buffer A and loaded onto a Source 15Q column previously equilibrated in the same buffer. After the column was washed with five column volumes of buffer A, the proteins were eluted with a linear gradient of 0--1 M NaCl in buffer A. The enzyme activity eluted from 0.3 to 0.45 M NaCl. These fractions were loaded onto a HisTrap HP column previously equilibrated with buffer B. After the column was washed with five column volumes of buffer B, the proteins were eluted with a linear gradient of 0--0.5 M imidazole in buffer B. The enzyme eluted from column at a concentration range of 0.12--0.19 M imidazole. These fractions were combined, dialyzed overnight against buffer D (20 mM sodium acetate, pH 6.0), and subsequently loaded onto a Source 15S column previously equilibrated in buffer D. After the column was washed with five column volumes of buffer D, the proteins were eluted with a linear gradient of 0--1 M NaCl in buffer D. Active EngCP fractions (eluting from 0.45 to 0.60 M NaCl) were combined and concentrated with a Centricon Concentrator 10 (Millipore, Billerica, MA) to about 5 mL. Concentrated samples were loaded onto a Superdex 75 column previously equilibrated with buffer E (20 mM sodium acetate, pH 6.0, 200 mM NaCl) and washed with buffer E. Fractions with EngCP activity were pooled and concentrated. After the addition of glycerol at 50%, the purified enzyme preparation was stored at −20°C.

EngPA purification {#S4-4}
------------------

The cell extract was diluted 3-fold with buffer A and loaded onto a Source 15Q column previously equilibrated in the same buffer. After the column was washed with five column volumes of buffer A, the majority of the EngPA activity was detected in the flow through. This was dialyzed against buffer D and loaded onto a Source 15S column previously equilibrated in buffer D. The column was washed with five column volumes of buffer D and EngPA activity was eluted with a linear gradient of 0--1 M NaCl in buffer D. Active EngPA fractions (eluting from 0.31 to 0.36 M NaCl) were combined, concentrated (5 mL), and loaded onto a Superdex 75 column previously equilibrated with buffer E. The column was washed with buffer E and fractions with EngPA activity were pooled and concentrated. After the addition of glycerol at 50%, purified enzyme preparation was stored at −20°C.

Assay of endo-α-GalNAcase activity {#S4-5}
----------------------------------

The hydrolytic activity of the enzymes was assayed using Galβ1,3GalNAcα1*p*NP as a substrate. A 100 μL standard reaction mixture contained a 50 mM sodium phosphate buffer, pH 7.5, 5 mM MgCl~2~, and 0.25 mM substrate. The time-dependent release of *p*-nitrophenol (*p*NP) at room temperature was measured by reading the absorbance at 405 nm using a 96-well plate reader (SpectraMax M5, Molecular Devices, Inc., Sunnyvale, CA). Pure protein samples were used for the kinetic measurements. Endo-α-GalNAcases from *S. pneumoniae* (EngSP) and *Alcaligenes* sp. (EngAL) were purchased from Roche (Basel, Switzerland) and Seikagaku Corporation (Tokyo, Japan), respectively. The substrate specificity was determined using various *p*NP glycosides and natural glycoproteins. The substrates Galβ1,3GalNAcα1*p*NP (CAS 59837-14-8), GlcNAcβ1,3GalNAcα1*p*NP (CAS 125455-64-3), Galβ1,3GlcNAcα1*p*NP (CAS 57467-13-7), GalNAcα1*p*NP (CAS 23646-68-6), calf κ-casein, human glycophorin A, porcine mucin, calf fetuin, and calf asialofetuin were purchased from Sigma. Galβ1,3(GlcNAcβ1,6)GalNAcα1*p*NP (CAS 139459-55-5) was from Toronto Research Chemicals Inc. (North York, Ontario). For TLC analysis, a Silica Gel 60 plate (Merck, Whitehouse Station, NJ) was developed in a solvent system of chloroform/methanol/water, 3/3/1 (v/v/v), and the sugars were visualized by spraying a diphenylamine/aniline/phosphate reagent ([@C4]).

Transglycosylation assays {#S4-6}
-------------------------

The 15 μL transglycosylation reaction mixture contained a 50 mM sodium phosphate buffer, pH 7.5, 5 mM MgCl~2~, 0.8 mM GlcNAcβ1,3GalNAcα1*p*NP or 1.6 mM Galβ1,3GalNAcα1*p*NP as donors, 0.8 μg of endo-α-GalNAcase and various 1-alcanols as acceptors (13%, v/v). The reactions were incubated at room temperature for 16 h. Methanol, ethanol, 1-propanol, 1-butanol, 1-pentanol, 1-hexanol, 1-heptanol, 1-octanol, and 1-nonalol were purchased from Sigma (St. Louis, MO). The transglycosylation reaction mixtures were analyzed on a Silica Gel 60 TLC plate using chloroform/methanol/water 65/35/8 as the developing solvent and the sugars were visualized by spraying a diphenylamine/aniline/phosphate reagent.

Optimum pH {#S4-7}
----------

The pH optimum for each enzyme was determined in a pH range of 2.0--9.0 using the following buffers (50 mM): glycine--HCl (2.0--4.0), sodium acetate (3.5--6.0), sodium phosphate (5.5--8.0), and Tris--HCl (7.0--9.0).

Enzyme kinetics {#S4-8}
---------------

Steady-state enzyme kinetics were performed at 25°C. The program HYPER v 1.01 was used to determine *V*~max~ and *K*~m~ values. The *k*~cat~ values were calculated from *V*~max~ using a molecular mass of 188,000 Da for EngCP, 147,000 Da for EngEF, 142,000 Da for EngPA, 190,000 Da for EngSP, and 160,000 Da for EngAL. Reported values are the average of three measurements. The standard deviations do not exceed 5%.
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